Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide derived from a protein found in the human gastric juice. Over the past decade it has attracted considerable attention in preclinical research for its remarkable regenerative properties.
Mechanism of Action
BPC-157 exerts its effects primarily through the modulation of the growth hormone (GH) receptor pathway. In-vitro studies have demonstrated that it can up-regulate GH receptors in tendon fibroblasts, dramatically accelerating matrix remodelling and collagen synthesis.
Additionally, BPC-157 promotes angiogenesis — the formation of new blood vessels — in injured tissue. This improves nutrient and oxygen delivery to the repair site, reducing overall healing time.
“BPC-157 represents one of the most promising peptide candidates for accelerating tissue regeneration in both musculoskeletal and gastrointestinal models.” — Journal of Physiology, 2024
Key Research Findings
- Tendon-to-bone healing improved by up to 40% in rodent models (Sikiric et al., 2023)
- Significant reduction in oxidative stress markers at the injury site
- NO-system mediated: BPC-157 activates the nitric oxide pathway to regulate vascular tone
- Superior healing of muscle, ligament, and gastric tissue in multiple animal models
Dosing Protocols in Research
The most commonly studied concentration in preclinical models ranges from 1–10 µg/kg administered either intraperitoneally or subcutaneously. The peptide demonstrates a notably wide therapeutic window with no established LD50 in animal studies to date.
Current Limitations
Despite compelling preclinical data, BPC-157 has not yet completed Phase II clinical trials in humans. All research referenced here is conducted under controlled laboratory conditions. Blueprint Sciences supplies this compound exclusively for in-vitro and research use.
As the field advances, researchers continue to refine understanding of the precise molecular targets and optimal concentration ranges needed for translatable results.